States seek to expand lawsuit against generic drugmakers

October 31, 2017
States seek to expand lawsuit against generic drugmakers
In this Tuesday, Feb. 5, 2013, file photo, Connecticut Attorney General George Jepsen speaks at the Justice Department in Washington. On Tuesday, Oct. 31, 2017, Jepsen and 45 of his colleagues sought to expand a federal antitrust lawsuit against generic drugmakers to include more manufacturers and medications, as well as senior executives at two companies. (AP Photo/Jacquelyn Martin, File)

Connecticut's attorney general and 45 of his colleagues are seeking to expand a federal antitrust lawsuit against generic drugmakers to include more manufacturers and medications, as well as senior executives at two companies.

Led by Connecticut, the states sought a federal court's permission Tuesday to widen their complaint, which alleges a number of illegal agreements among 18 manufacturers to fix prices and divvy up the market for specific generic drugs including treatments for high blood pressure, arthritis and asthma.

Mylan N.V., one of the drugmakers named in the suit, said it has investigated the allegations thoroughly and "found no evidence of price fixing." Mylan also said it stands by Rajiv Malik, its president since January 2012 who was named in the expanded complaint.

Based outside of Pittsburgh, Mylan makes a range of generic and branded drugs, including the EpiPen emergency allergy injector. Shares of the company slid 6.6 percent to close at $35.71.

The original lawsuit filed last year claimed six drugmakers artificially inflated and manipulated prices for two drugs, an antibiotic and a diabetes drug. At the time, Connecticut Attorney General George Jepsen said "it was just the tip of the iceberg."

Jepsen said Tuesday the alleged collusion is "so pervasive that it essentially eliminated competition from the market" for 15 generic drugs.

Explore further: States seek to expand lawsuit against generic drug-makers

Related Stories

States seek to expand lawsuit against generic drug-makers

October 31, 2017
Connecticut's attorney general and 45 of his colleagues are seeking to expand a federal antitrust lawsuit against generic drug-makers to include more manufacturers and medications, as well as senior executives at two companies.

Generic drugmakers want antitrust lawsuit dismissed

May 3, 2017
Six generic drugmakers are asking a federal judge in Connecticut to dismiss a 40-state lawsuit accusing them of artificially inflating and manipulating prices to reduce competition for antibiotic and oral diabetes medication.

Connecticut leads 20-state lawsuit over drug pricing

December 15, 2016
Six generic drug-makers artificially inflated and manipulated prices to reduce competition for an antibiotic and oral diabetes medication, 20 state attorneys general, led by Connecticut, said in a federal lawsuit filed Thursday.

EpiPen maker finalizes settlement for government overcharges

August 17, 2017
EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade—charges brought after rival Sanofi filed a whistleblower ...

Mylan, like other generic drugmakers, feels the pricing pain

August 9, 2017
Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory ...

FDA takes steps to boost generic competition, limit prices

June 27, 2017
The Food and Drug Administration is taking steps to boost the number of generic prescription drugs in an effort to make medicines more affordable and to prevent price gouging.

Recommended for you

Health insurance plans may be fueling opioid epidemic

June 22, 2018
Health care insurers including Medicare, Medicaid and major private insurers have not done enough to combat the opioid epidemic, suggests a study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Overdose risk quintuples with opioid and benzodiazepine use

June 22, 2018
In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients, according to a new study from the University ...

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

BubbaNicholson
1 / 5 (2) Nov 01, 2017
This is wrong headed and stupid. 250mg of healthy adult male facial skin surface lipid p.o. cures opioid addiction in 8 seconds. Avoid the vapors.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.